

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number  
**WO 2004/018708 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**

MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/EP2003/008298

(22) International Filing Date: 28 July 2003 (28.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02017758.0 9 August 2002 (09.08.2002) EP

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,  
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO  
patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,  
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,  
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(71) Applicant (*for all designated States except US*): BAYER  
HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SCHWERS,  
Stephan [DE/DE]; Düsseldorf Str. 35, 51145 Köln  
(DE). KALLABIS, Harald [DE/DE]; Wolfskaul 8, 51061  
Köln (DE). REIFENBERGER, Elke [DE/DE]; Kölnstr.  
67, 53757 Sankt Augustin (DE). STROPP, Udo [DE/DE];  
Suißbertusweg 8, 42781 Haan (DE). SCHMITZ, Gerd  
[DE/DE]; Turmstr. 15a, 93161 Sinzing (DE).

(74) Common Representative: BAYER HEALTHCARE  
AG; Law and Patents, Patents and Licensing, 51368  
Leverkusen (DE).

**Published:**

— without international search report and to be republished  
upon receipt of that report

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 2004/018708 A2

(54) Title: GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG REACTIONS (ADR) AND DRUG  
EFFICACY

(57) **Abstract:** The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including  
as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether  
the human subject is a high or low responder or a good or a bad metabolizer of statins. The invention provides further diagnostic  
methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the  
invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encod-  
ing a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a  
medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising:  
SEQ ID 1-21 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA  
for PA gene polypeptide and with or without the PA gene promoter sequence.